About Tamar
As a transformational executive and market access champion, Tamar Thompson has an impressive history in leading the complexities of health policy strategy and addressing the range of issues related to improving health outcomes.
Tamar is a visionary thought leader who has leveraged her extensive pharmaceutical commercialization and launch strategy experience to work across the healthcare continuum and ensure optimal market entry and patient access to breakthrough and curative therapies.
Prior to joining Alexion/AstraZeneca Rare Disease, Tamar lead Federal Executive Branch Strategy and State Government Affairs for Bristol-Myers Squibb Company. Mrs. Thompson also served as a policy advisor and consultant for three premiere Washington DC based firms, ADVI, Kimbell & Associates and Avalere Health, where she managed a diverse portfolio of clients, including medical device, biotech, pharmaceutical, diagnostics, and specialty drug companies.
Preceding her time in Washington DC, Mrs. Thompson was Director of Health Policy & Reimbursement at Molecular Insight Pharmaceuticals (now Progenics) where she was charged with developing and launching reimbursement and market access strategy for cutting-edge molecular diagnostic and therapeutic treatments options. Additionally, she held health policy and reimbursement leadership roles at GE Healthcare and Bracco Diagnostics.
Notably, her experience extends beyond the life sciences community as she has also held several senior leadership roles within the managed care sector for Humana and ValueOptions (now Beacon Health Options).
Today, Tamar serves on the board of directors for Avidity Bioscience, a clinical phase rare disease company. Concurrently, she sits on the executive committee and serves as a director for MassBio, a state level trade association for the life science community, and Healthy Women, a patient empowerment organization. She also sits on the Schwartz Center (Mass General Hospital) Leadership Council.
Tamar holds a M.S. in Health Sciences with a concentration in Public Health from Trident University in Cypress California and an Executive Leadership certificate from Columbia University. She is currently participating in the Berkeley NextGen Directors Program focused on corporate governance education and training for the next generation of diverse executives.